This company has been marked as potentially delisted and may not be actively trading. Sinovac Biotech (SVA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendHeadlinesOptions ChainTrendsBuy This Stock SVA vs. MLTX, XENE, AMRX, OGN, HCM, MIRM, APLS, ARWR, NAMS, and GMTXShould you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include MoonLake Immunotherapeutics (MLTX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), HUTCHMED (HCM), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical preparations" industry. Sinovac Biotech vs. MoonLake Immunotherapeutics Xenon Pharmaceuticals Amneal Pharmaceuticals Organon & Co. HUTCHMED Mirum Pharmaceuticals Apellis Pharmaceuticals Arrowhead Pharmaceuticals NewAmsterdam Pharma Gemini Therapeutics MoonLake Immunotherapeutics (NASDAQ:MLTX) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking. Is MLTX or SVA more profitable? Sinovac Biotech's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -15.54% -15.09% Sinovac Biotech N/A N/A N/A Does the media prefer MLTX or SVA? In the previous week, MoonLake Immunotherapeutics had 11 more articles in the media than Sinovac Biotech. MarketBeat recorded 14 mentions for MoonLake Immunotherapeutics and 3 mentions for Sinovac Biotech. MoonLake Immunotherapeutics' average media sentiment score of 1.07 beat Sinovac Biotech's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sinovac Biotech 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate MLTX or SVA? MoonLake Immunotherapeutics presently has a consensus target price of $78.71, indicating a potential upside of 102.19%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, MLTX or SVA? MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Does the MarketBeat Community favor MLTX or SVA? Sinovac Biotech received 185 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.82% of users gave MoonLake Immunotherapeutics an outperform vote while only 67.99% of users gave Sinovac Biotech an outperform vote. CompanyUnderperformOutperformMoonLake ImmunotherapeuticsOutperform Votes7281.82% Underperform Votes1618.18%Sinovac BiotechOutperform Votes25767.99% Underperform Votes12132.01% Which has stronger earnings and valuation, MLTX or SVA? MoonLake Immunotherapeutics has higher earnings, but lower revenue than Sinovac Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$36.01M-$2.30-16.93Sinovac Biotech$448.27M1.44-$99.92MN/AN/A Do insiders & institutionals have more ownership in MLTX or SVA? 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryMoonLake Immunotherapeutics beats Sinovac Biotech on 9 of the 14 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSinovac BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.67M$6.46B$5.34B$8.31BDividend YieldN/A2.63%5.27%4.10%P/E RatioN/A8.4426.9619.60Price / Sales1.44258.98399.08136.08Price / Cash38.9565.8538.3234.64Price / Book0.056.416.774.50Net Income-$99.92M$143.95M$3.24B$248.60M Sinovac Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261News CoverageHigh Trading VolumeMLTXMoonLake Immunotherapeutics3.1457 of 5 stars$39.20+4.2%$78.71+100.8%-2.6%$2.51BN/A-30.392Positive NewsGap UpXENEXenon Pharmaceuticals3.251 of 5 stars$30.95+2.2%$54.82+77.1%-22.6%$2.37B$7.50M-10.98210Positive NewsAnalyst DowngradeAMRXAmneal Pharmaceuticals3.1542 of 5 stars$7.50-1.3%$11.50+53.3%+11.2%$2.35B$2.83B-11.037,600Positive NewsOGNOrganon & Co.4.7453 of 5 stars$9.00-0.4%$18.00+100.0%-59.3%$2.35B$6.29B2.7010,000Trending NewsGap DownHCMHUTCHMED2.4315 of 5 stars$13.48+0.7%$19.00+40.9%-28.4%$2.35B$630.20M0.001,760News CoveragePositive NewsAnalyst DowngradeGap DownMIRMMirum Pharmaceuticals4.0529 of 5 stars$44.89-0.3%$60.73+35.3%+72.8%$2.22B$379.25M-22.22140News CoveragePositive NewsAnalyst RevisionAPLSApellis Pharmaceuticals4.1916 of 5 stars$17.67+1.3%$40.42+128.8%-56.0%$2.22B$775.84M-8.70770Analyst ForecastARWRArrowhead Pharmaceuticals3.5131 of 5 stars$15.74+0.2%$42.13+167.6%-38.7%$2.17B$545.21M-3.04400News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap UpNAMSNewAmsterdam Pharma2.6374 of 5 stars$19.03+0.8%$43.00+126.0%-7.8%$2.09B$47.14M-10.124Positive NewsAnalyst DowngradeGMTXGemini TherapeuticsN/A$48.09+2.1%N/A+44.8%$2.08BN/A-48.0930News CoverageHigh Trading Volume Related Companies and Tools Related Companies MLTX Alternatives XENE Alternatives AMRX Alternatives OGN Alternatives HCM Alternatives MIRM Alternatives APLS Alternatives ARWR Alternatives NAMS Alternatives GMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SVA Stock Free SVA Stock Alerts